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Abstract: Diabetes mellitus is a heterogeneous and dysmetabolic chronic disease in which the
laboratory plays a fundamental role, from diagnosis to monitoring therapy and studying complications.
Early diagnosis and good glycemic control should start as early as possible to delay and prevent
metabolic and cardio-vascular complications secondary to this disease. Glycated hemoglobin is
currently used as the reference parameter. The accuracy of the glycated hemoglobin dosage may
be compromised in subjects suffering from chronic renal failure and terminal nephropathy, affected
by the reduction in the survival of erythrocytes, with consequent decrease in the time available
for glucose to attach to the hemoglobin. In the presence of these renal comorbidities as well as
hemoglobinopathies and pregnancy, glycated hemoglobin is not reliable. In such conditions, dosage
of glycated albumin can help. Glycated albumin is not only useful for short-term diagnosis and
monitoring but predicts the risk of diabetes, even in the presence of euglycemia. This protein is
modified in subjects who do not yet have a glycemic alteration but, as a predictive factor, heralds the
risk of diabetic disease. This review summarizes the importance of glycated albumin as a biomarker
for predicting and stratifying the cardiovascular risk linked to multiorgan metabolic alterations.
Keywords: glycated albumin; diabetes; dyslipidemia; obesity; kidney disease; therapy; cardiovascular
disease; cerebrovascular disease
1. Introduction
In the context of precision medicine, it would be desirable to estimate the “cardiometabolic risk”
of each individual by evaluating the presence of risk factors which could influence the metabolism
leading to increased cardiovascular mortality [1–3].
Glycated Albumin (GA) [4–6] represent a useful tool reflecting glycemic homeostasis over a period
of three weeks. GA provides a qualitatively and quantitatively significant contribution to the clinical
process of screening, prediction, prevention, diagnosis, prognosis and monitoring of the metabolic
disorders of several organs [7–9].
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GA, a unique post-translational product of the glycosylation of albumin, has been shown to be a
useful biomarker in: (i) clinical conditions in which the dosage of glycated hemoglobin (HbA1c) does not
reflect glycemic compensation, such as chronic renal failure, gestational diabetes, dialysis complications,
hemorrhages, recent transfusions, hemolytic anemia and hemoglobin variants [6,9–13]; (ii) patients with
poorly controlled diabetes and with postprandial hyperglycemia in order to monitor short-term glycemic
fluctuation [14,15]; (iii) diabetic patients for monitoring therapeutic response [16–19]; (iv) detecting
prediabetes even in the presence of normoglycemia, which is a priority because the effectiveness of this
lifestyle intervention is lost if diabetes has already developed [20,21]. It is well known that fructosamine
represents all the circulating glycated proteins, therefore Glycated Albumin is biochemically recognized
as a form of fructosamine [14]. With the Oral Glucose Tolerance Test (OGTT) as the diagnostic
standard [11,22], GA has been shown to be superior to fructosamine alone in detecting hyperglycemic
states [8,23]. Moreover, the GA/HbA1c ratio is very important from a diagnostic point of view to detect
patients with postprandial hyperglycemia or large glycemic excursion [15,24].
The aim of this review is to describe GA’s contribution in diabetes and metabolic conditions and
to present its potential usefulness for predicting and stratifying cardiometabolic risk.
2. Search Strategy
Using electronic databases [MEDLINE (1975–2020), EMBASE and SCOPUS (2000–2020)] and
abstracts from national and international meetings, we searched for interventional and observational
studies in humans which assessed the association between glycated albumin and cardiometabolic
risk factors. A total of 74 studies were included in the present review, extracted using combinations
of the following keywords: glycated albumin, diabetes, dyslipidemia, obesity, kidney disease,
cardiovascular risk, and therapy.
3. Glycated Albumin (GA)
Albumin is the most abundant plasma protein, with a half-life of about 21 days, that undergoes
non-enzymatic glycosylation due to its high circulating concentration, the number of lysine and
arginine residues making it more prone to glycation [6,25].
The protein consists of 585 amino acid residues organized in a single polypeptide chain stabilized
by 17 disulfide bridges and comprising three homologous domains (I, II, and III) assembled to
form a heart-shaped molecule. Each domain is further organized into two subdomains (A and B),
which share analogous structural motifs. The glycation-induced modifications significantly alter the
structure of the two subdomains of the second domain. These two subdomains act as binding sites,
with preferential activity for different endogenous substrates (such as bilirubin and porphyrins),
and exogenous compounds (such as benzodiazepines and ibuprofen).
The glycation process also modifies the n-terminal region and the Cysteine (Cys)-34 of albumin.
Both regions are involved in the binding of drugs and various metal cations. GA can contain both
early and advanced glycation products [7,26]. The latter can derive both from the transformation of
early adducts already present at the protein level, and from new interactions between the protein
and preformed early glycation products [27]. Both the reduction of circulating levels and structural
changes capable of modifying biochemical and physical properties of the protein can alter the binding
properties of albumin against multiple drugs, and reduce its antioxidant and scavenger power [28,29]
(Figure 1). Therefore, the glycation process of albumin causes potential changes in the therapeutic
and/or toxic effects of all the drugs that bind albumin, with a significant variation mainly for agents
acting in a relatively narrow therapeutic window [30]. It is possible that the reduced binding capacity
towards fatty acids [31], especially arachidonic acid, is associated with an increased thrombotic risk in
patients with metabolic syndrome and diabetes [32,33].
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Figure 1. Schematic representation of the main physiological functions of albumin and pathological 
actions after specific glycation processes; ROS: reactive oxygen species; N = O: nitric oxide; ICAM-1: 
intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1. 
GA Test 
The American Diabetes Association (ADA) and the European Association Diabetes Study 
(EASD) recommend “patient-centered” management of glycemic control in patients with Type 2 
Diabetes Mellitus (T2DM) and the selection only of biomarkers, such as GA, that reflect the individual 
health status of the diabetic patient, maintaining the balance between risks and benefits [34]. 
The GA test provides information on the mean blood glucose concentration in the last 15–20 
days before blood collection [4,6,8,11,19,24]. 
The GA can be measured by several methods, including affinity chromatography, ion exchange, 
high-performance liquid chromatography and immunoassays (such as enzyme-linked immune-
sorbent assays and radio-immunoassays) (as reviewed in [35,36]). GA can be measured on both 
serum and plasma, where it is stable both for 24 h at room temperature, or at 4 °C for a week, or at 
−80 °C for several months [5,34]. 
Recently, an innovative and very promising electrochemical immunoassay using nanozymes has 
also been developed, showing good linearity and a lower limit of detection [37]. 
Interestingly, an enzymatic method that shows good analytical performance has also recently 
been automated (Lucic®  GA-L kit, Asahi Kasei Pharma Corporation, Tokyo, Japan). The method is 
based on the initial elimination of endogenous glycated amino acids and peroxides mediated by a 
ketamine oxidase and a peroxidase. The GA is then hydrolyzed by an albumin-specific proteinase, 
and the products of this reaction are oxidized by a ketamine oxidase. The hydrogen peroxide 
produced is then measured quantitatively by the classic colorimetric method of Trinder. Meanwhile, 
in parallel, the concentration of albumin is measured by the bromocresol violet method, allowing the 
results to be expressed as the ratio between GA and total albumin [38,39]. The result of GA is 
provided as a percentage (GA%) of total albumin. The GA Upper Reference Limit (URL) of 14.5% 
(95% CI: 14.3–14.7) has been established in Caucasian healthy subjects [5]. 
4. GA and Cardio-Metabolic Risk Factors 
High GA levels can induce irreversible damage in several organs, which represent the main 
targets for complications of diabetes mellitus (e.g., the coronary arteries, the cardiovascular system, 
the kidneys, the thyroid, the skeletal muscles, the eyes, and the central nervous system). 
For example, in the kidney, GA stimulates epithelial and mesangial cells to produce pro-oxidant 
molecules and connective tissue, thus contributing to the onset of nephropathy [40–43]. 
Figure 1. Schematic representation of the main physiological functions of albumin and pathological
actions after specific glycation processes; ROS: reactive oxygen species; N = O: nitric oxide; ICAM-1:
intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1.
GA Test
The American Diabetes Association (ADA) and the European Association Diabetes Study (EASD)
recommend “patient-centered” management of glycemic control in patients with Type 2 Diabetes
Mellitus (T2DM) and the selection only of biomarkers, such as GA, that reflect the individual health
status of the diabetic patient, maintaining the balance between risks and benefits [34].
The GA test provides information on the mean blood glucose concentration in the last 15–20 days
before blood collection [4,6,8,11,19,24].
The GA can be measured by several methods, including affinity chromatography, ion exchange,
high-performance liquid chromatography and immunoassays (such as enzyme-linked immune-sorbent
assays and radio-immunoassays) (as reviewed in [35,36]). GA can be measured on both serum
and plasma, where it is stable both for 24 h at room temperature, or at 4 ◦C for a week, or at −80 ◦C for
several months [5,34].
Recently, an innovative and very promising electrochemical im unoassay using nanozymes has
also been developed, showing good linearity and a lower limit of detection [37].
Interestingly, an enzymatic method that shows good analytical performance has also recently
been automated (Lucic® GA-L kit, Asahi Kasei Pharma Corporation, Tokyo, Japan). The method is
based on the initial elimination of endogenous glycated amino acids and peroxides mediated by a
ketamine oxidase and a peroxidase. The GA is then hydrolyzed by an albumin-specific proteinase,
and the products of this reaction are oxidized by a ketamine oxidase. The hydrogen peroxide produce
is then measured quantitatively by the classic colorimetric method of Trinder. Meanwhile, in parallel,
the concentration of albumin is measured by the bromocresol violet method, allowing the results to
be expressed as the ratio between GA and total albumin [38,39]. The result of GA is provided as a
percentage (GA%) of total albumin. The GA Upper Reference Limit (U L) of 14.5% (95% CI: 14.3–14.7)
has been established in Caucasian healthy subjects [5].
4. GA and Cardio-Metabolic Risk Factors
High GA levels can induce irreversible damage in several organs, which represent the main
targets for complications of diabetes mellitus (e.g., the coronary arteries, the cardiovascular system,
the kidneys, the thyroid, the skeletal muscles, the eyes, and the central nervous system).
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For example, in the kidney, GA stimulates epithelial and mesangial cells to produce pro-oxidant
molecules and connective tissue, thus contributing to the onset of nephropathy [40–43].
In the field of cardiovascular diseases, GA exerts pro-inflammatory and pro-oxidant effects
on cardiomyocytes [44], playing a role in the activation and aggregation of platelets [32], and also
regulating the expression of adhesion molecules involved in the formation of atherosclerotic plaques,
such as the InterCellular Adhesion Molecule (ICAM)-1 and the Vascular Cell Adhesion Molecule
(VCAM)-1 [45], but also promoting deleterious oxidation [46].
Cells of the skeletal muscle are also sensible to the increased concentrations of GA, which stimulate
an over-expression of inflammatory cytokines [47].
Furthermore, a significant association between thyroid hormones and GA in both euthyroid and
subclinical hypothyroid individuals has recently been described [48].
At the metabolic level, the increased intracellular production of reactive oxygen species (ROS)
may reduce the secretion of insulin [49]. GA exerts its harmful effects by the activation of the cellular
receptor for advanced glycation end products (RAGEs). Indeed, the activation of RAGEs stimulates
the production of pro-inflammatory cytokines, and induces apoptosis, oxidative stress, and platelet
aggregation, events that have been associated with the increase of AGE levels and GA levels [50].
In the following subparagraphs, the correlation between GA and cardiometabolic risk factors
such as diabetes, dyslipidemia, obesity, kidney disease and cerebro-cardiovascular diseases will be
described in detail (Figure 2).
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Figure 2. Schematic diagram of GA correlations with metabolic and vascular parameters. The cited
parameters are divided into two groups based on their negative or positive correlation with GA and
are reported in the same color as the risk factor to which they refer. (baPWV: brachial-ankle Pulse
Wave Velocity; BMI: Body Mass Index; CIMT: Carotid Intima-Media Thickness; FPG: Fasting Plasma
Glucose; GA: Glycated Albumin; HbA1C: Hemoglobin A1c; hsCRP: high sensitivity C Reactive Protein;
LDL-C: Low-Density Lipoprotein Cholesterol; TNF-α: Tumor Necrosis Factors-α; UPE: Urinary
Protein Excretion; VCAM-1: Vascular Cell Adhesion Molecule-1; HOMA-IR: homeostatic model
assessment-insulin resistance; poC-III: apolipoprotein C-III).
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4.1. GA and Diabetes
The pathogenesis of T2DM is linked to insulin-resistance, which leads to a slow decline of
pancreatic β-cells; both pathological states influence each other and, presumably, synergistically
exacerbate diabetes inducing the failure of insulin over time [51].
In addition to the use of HbA1c for the diagnosis of diabetes [52], the use of additional glycated
proteins for this diagnosis and its complications has been widely recommended [11].
The glycation rate of albumin is greater than that of hemoglobin and would reflect early
hyperglycemia before HbA1c [8,53].
4.1.1. GA and Diabetes Diagnosis
As a medium-term glycemic status indicator, GA is originally taken into consideration for
the diagnosis of diabetes in patients with hemoglobinopathies and other conditions in which the
measurement of HbA1c is not reliable [4,6,52,54]. It has also been assessed in screening programs to
detect individuals with prediabetes [23,25]. It is necessary to discern the various conditions related
to diabetes and to assess the value of GA based on the presence of comorbidity [35]. For example,
Koga et al. reported that serum GA levels are significantly lower than HbA1c in diabetic patients with
preserved insulin secretion [55–57].
The homeostasis model assessment ofβ-cell function (HOMA-β), an index of insulin secretory function,
is negatively correlated with GA, but is not correlated with HbA1c. Indeed, it has been assumed that
this phenomenon is due to the association between reduced insulin secretion and increased glucose
excursions, including postprandial hyperglycemia [49].
4.1.2. GA and Monitoring of Diabetes Treatment
The evaluation of the efficacy of therapy in diabetic patients is mandatory in order to avoid
glycemic failure and its consequences.
GA levels may be useful in predicting the patient’s response to hypoglycemic therapy. Lee et al.
performed a study on Korean patients with poorly controlled insulin-naive T2DM. These subjects
were randomized based on obesity and the dose of glimepiride with a 1:1 ratio of insulin detemir
(prolonged-action analog) and Biphasic Insulin (rapid-action analog) [58]. Mean HbA1c, GA, fasting and
stimulated plasma glucose levels were significantly reduced after 16 weeks [58]. GA decreased more
rapidly than HbA1c during intensive insulin therapy. Thus, GA has been considered a useful
biomarker for monitoring short-term variations of glycemic control during the treatment of diabetic
patients [58,59].
GA could also be potentially useful for monitoring the beneficial effects of nutraceuticals. Li et al.
performed a double-blind, randomized, placebo-controlled study to evaluate fiber supplementation
during a 12 week integration period [60]. All glucose metabolism biomarkers, including HOMA-Insulin
Resistance, HbA1C and GA, improved after 12 weeks.
4.2. GA and Dyslipidemia
4.2.1. GA and Dyslipidemia Diagnosis
Dyslipidemia is a clinical condition frequently found in diabetic patients. It is characterized
by the alteration of lipid metabolism. Specifically, diabetes is associated with hypertriglyceridemia
due to increased levels of very low density lipoprotein (VLDL), which are enriched by Apo-CIII
(apolipoprotein c-III). Indeed, patients with T1DM and T2DM have increased ApoC-III levels [61].
It has been shown that the inhibition of ApoC-III can improve dyslipidemia in diabetic patients [62].
The underlying mechanism could be the improvement of lipoprotein lipase (LPL) activity and the
increased hepatic uptake of triglyceride-rich lipoprotein (TRL) [62]. A strong relationship between
improved insulin sensitivity and ApoC-III suppression has been described [62,63]. Park et al. found that
patients with GA > 17.0% showed a direct and significant correlation with fasting plasma glucose (FPG),
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TC (total cholesterol), TG (triglyceride), and LDL-C (low density lipoprotein-cholesterol), as compared
to patients with GA ≤ 17.0% [63]; these findings indicate that GA can be used as a tool for screening
high-risk diabetic patients for early diagnosis of dyslipidemia.
4.2.2. GA and Monitoring of Dyslipidemia Treatment
Patients with dyslipidemia who do not reach the LDL-C target via lifestyle changes only or with
nutraceuticals undergo hypocholesterolemia therapy, such as statins. Despite the numerous beneficial
effects of statins, especially atorvastatin and rosuvastatin, on LDL levels [64–67], some collateral effects,
collectively known as statin intolerance (SI) syndrome, have been reported. Specifically, SI syndrome
is characterized by the increase of creatine-phosphokinase (CPK) and other bio humoral biomarkers
(such as lipase and amylase) as well as glucose homeostasis alterations, which can lead to the
development of diabetes [68–72]. GA could represent a useful biomarker for monitoring the
effect of hypocholesterolemia treatment on glucose homeostasis, as shown by some authors [73].
A randomized, double-blind, placebo-controlled study was conducted in adult patients with T2DM
and hypertriglyceridemia treated with metformin and volanesorsen, respectively [74]. Volanesorsen
improved insulin sensitivity, which was associated with a decrease in GA and HbA1c levels [74].
These data suggest that GA could be used for monitoring the efficacy of lipid-lowering therapies [63].
4.3. GA and Obesity
The World Health Organization (WHO) defines obesity as “abnormal or excessive fat accumulation
that represents a risk to health”. A BMI (body mass index) > 29.9 kg/m2 identifies obese patients.
More in-depth research has consistently revealed that HbA1c is positively associated with BMI,
while GA is negatively associated with BMI [75]. Recently a study exploring the association of waist
circumference (WC) with GA and to assess the extent to which WC influences GA showed that GA
levels and GA/HbA1c ratio were further decreased in subjects with central obesity than those without,
suggesting that WC was a significant negative determinant of GA [76]. Thus, GA could not be a
reliable biomarker of glucose homeostasis in obese subjects. Similarly, Sumner et al. found that, in
obese subjects, the HbA1c was a much better diagnostic test than the GA [77] and the combination of
the tests did not improve the diagnostic sensitivity [77,78].
In a study including subjects with normal and reduced glucose tolerance, BMI was found to be
negatively associated with GA and GA/HbA1c ratio. Interestingly, the inflammatory status was associated
positively with BMI and negatively with GA [79], confirming data previously described [80,81].
Several studies assessed the negative relationship between BMI and GA in the diabetic
population [81–83], revealing a negative relationship between BMI and GA in diabetes.
Although a correlation between BMI and the GA/HbA1c ratio has been reported [80], contradictory
studies have showed that the reduction of BMI is associated with a high GA/HbA1c ratio [15], whereas
other studies reported that there is an inverse association between BMI and GA/HbA1c ratio in subjects
with various states of glucose tolerance [84]. Thus, further studies are mandatory in order to clarify the
relationship between BMI and GA/HbA1c ratio.
The relationship between BMI and GA levels in diabetic and non-diabetic patients has been
evaluated [83], revealing that a decreasing trend in GA levels and GA/HbA1c ratio is associated with
an increasing trend in BMI, suggesting that BMI has a negative effect on the GA/HbA1c ratio [83]. In a
wide study, the association between serum GA and anthropometric variables revealed that patients
with BMI > 25.0 kg/m2 had significantly higher HbA1C and body fat parameters, but significantly
lower GA levels (p < 0.05) [75].
Overall, the evidence supports a negative relationship between BMI and GA, regardless of
the presence of diabetes [80,81,83]. The negative relationship between GA and BMI could be due
to the inverse correlation between BMI and total albumin. Indeed, obese subjects present chronic
inflammation, characterized by an increased release of cytokines from adipose tissue (adipocytokines),
which promote the synthesis of CRP in the liver [85] by reducing the synthesis rate and increasing
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the catabolic rate of the albumin [86]. That GA is a ketamine formed through the non-enzymatic
glycation reaction of serum albumin partly explains the relatively low concentration of GA in obese
patients [79,87,88].
4.4. GA and Kidney Diseases
Chronic kidney disease (CKD) is associated with insulin resistance and, in advanced CKD,
decreased insulin degradation. Thus, monitoring glycemic homeostasis in patients with CKD is
fundamental [89]. HbA1c remains the gold standard with CKD patients. However, some authors have
evaluated the role of GA in CKD patients [90].
4.4.1. Glycated Albumin and Kidney Disease Diagnosis
GA is associated with albumin turnover and it is still unclear whether proteinuria affects GA
values in diabetic patients with CKD [9]. Patients with advanced diabetic nephropathy and diabetic
patients with non-diabetic kidney disease exhibit evident and significant proteinuria. GA would
appear to be more accurate in evaluating glycemic control than HbA1c in patients with advanced
CKD [91].
Patients affected by nephrotic syndrome have an increase in albumin synthesis and in the fractional
catabolic rate, with consequent rapid albumin turnover [92,93]. Kidney function may not directly affect
GA values; however, higher levels of GA are associated with all-cause or cardiovascular mortality in
diabetic patients on hemodialysis [94].
The interpretation of GA may be limited in the context of CKD due to proteinuria and impaired
protein homeostasis and half-life [95]. The associations of HbA1c and GA with FPG showed a weak
correlation in dialysis patients compared to those not on dialysis [96], suggesting a recommendation
for GA, compared to HbA1c, for monitoring glycemic control in dialysis patients [8,97].
A study of diabetic patients with CKD revealed a significant correlation between GA and UPE [98].
In the Atherosclerosis Risk In Communities (ARIC) study, the association of HbA1c and GA
with FPG in different CKD categories revealed significant correlations of HbA1c and GA with FPG,
with lower levels in patients with severe chronic renal failure and very severe CKD [99].
A strong association of GA with retinopathy and with the risk of CKD and incident diabetes was
found, highlighting that the prediction of CKD by GA was almost as strong as by HbA1c [99,100].
Interestingly, the association between GA and arterial stiffness in CKD patients was analyzed [101],
revealing that patients not suffering from chronic renal failure but with arterial stiffness showed higher
GA levels than those without arterial stiffness, and that GA correlated significantly with both arterial
stiffness and FPG, while HOMA-IR (homeostatic model assessment-insulin resistance) did not show
any significant correlation with arterial stiffness.
The association between GA and the progression of Diabetic Nephropathy (DN) revealed that
mean GA levels were more closely associated with DN progression than HbA1c in T2DM patients [102].
In conclusion, serum GA is a potentially useful glycemic index in diabetic patients with chronic
renal failure, as it is not affected by anemia and associated treatments [102–104].
4.4.2. Glycated Albumin and Kidney Disease Treatment Monitoring
Drug therapy is different in the various stages of the disease. Specifically, in the initial stages
it is usually possible to administer therapy for the contrasting causes underlying the nephropathy.
In the advanced stages, it is necessary to adopt treatments to control complications of renal failure by
“poly-therapy” [89].
The Japanese Society for Dialysis Therapy recommended GA levels < 20.0% as a target for glycemic
control in patients without a history of cardiovascular events and GA level < 24.0% as a provisional
target for patients with a history of cardiovascular events or with a tendency to hypoglycemic
episodes [105].
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4.5. GA and Cerebro-Cardiovascular Diseases
There are various causes that determine cerebrovascular diseases, including atherosclerosis,
a pathological condition characterized by arterial inflammation and accumulation of cholesterol,
leading to the formation of thick plaques [106].
There is a strong correlation between GA and atheromatous plaque, as demonstrated by numerous
studies [101,107–117].
4.5.1. GA and Cerebro-Cardiovascular Diagnosis
A relationship among molecular (GA, HbA1c and CRP) and vascular (Carotid Intima Media
Thickness (CIMT)) biomarkers has been reported. Increased levels of GA have been associated with
increased levels of CRP and carotid atherosclerosis, especially when considering diabetic patients with
proven cardiovascular diseases [107]. Since GA levels have been proven to be independent predictors
of the presence of Coronary Artery Disease (CAD), GA can generally be used for decision making after
initiation or modification of therapy [109].
GA was found to be a more useful predictor for the presence of microangiopathy than HbA1c [100,110],
probably because GA is more closely related to glycemic fluctuation and excursion than HbA1c in
diabetic patients with poor glycemic control. Noteworthy, postprandial hyperglycemia contributes
more to cardiovascular events and the risk of death than fasting hyperglycemia [118,119]. GA represents
a more reliable indicator of the glycemic status than HbA1c in older subjects [120].
Recently, GA has been found to play a role in the increased arterial stiffness observed in
diabetic patients, due to the activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells
(NF-kB) in endothelial cells and the proliferation of vascular smooth muscle cells [121], regulating also
Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NADPH) oxidase and inducing sustained
production of ROS (reactive oxygen species) in human endothelial cells [122]. In this context,
GA stimulates Transforming Growth Factor beta (TGF-b) and increases oxidative stress, inducing
vasculopathy in experimental models [123].
GA has been associated with CIMT in patients with T2DM without any CAD and Peripheral
Artery Disease (PAD) [119], as well as in the general population [115].
Although further studies are required to clarify the mechanisms involved in the relationship
between GA and atherosclerosis, a possible cut-off value of GA for the prediction of CAD in patients
with diabetes was defined at 17.9% (sensitivity 0.639 and specificity 0.639) [119].
Recently, it has been highlighted that pre-stroke glucose variability estimated by GA was
significantly associated with an increased risk of severe initial stroke severity and large infarct volume
in acute ischemic stroke patients with diabetes mellitus [124], suggesting that GA could be a useful
tool for discerning/identifying early cerebrovascular disease.
In patients undergoing coronary artery Computed Tomography Angiography (CCTA), [116] the
CAD group showed significantly higher GA and HbA1c levels than the non-CAD group (p < 0.05)
with a positive correlation between GA and HbA1c (r = 0.551, p < 0.0001); in particular, GA (r: 1.30,
p = 0.02) was the only predictor of the presence of CAD in the diabetes mellitus group [116].
4.5.2. GA and Cerebro-Cardiovascular Treatment Monitoring
The Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events
(CHANCE) trial analysed 3044 patients with minor ischemic stroke or Transient Ischemic Attack (TIA)
from 73 predetermined clinical sites, who underwent measurement of baseline GA levels. Patients
were divided into two groups based on a GA level of 15.5%, considered the threshold value for the
development of diabetes [117]. The primary outcome was a stroke recurrence over 90 days of follow-up.
Patients with minor ischemic stroke or TIA were randomized to antiplatelet therapy with Clopidogrel
plus AcetylSalicylic Acid (ASA) or only ASA. A significant interaction of GA levels was found with the
two antiplatelet therapy groups after adjustment for age, gender and other conventional confounding
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factors (p = 0.009) and the interaction remained constant after further correction for diabetes history
(p = 0.010). In patients with the lowest GA levels, a stroke occurred in 5.5% of patients in the clopidogrel
+ ASA group and in 12.7% in the ASA only group (HR corrected: 0.40; 95% CI: 0.26–0.61; p < 0.001) [117].
In addition, in patients with elevated GA levels, stroke occurred in 9.2% of patients in the clopidogrel
+ ASA group and 11.4% in the ASA only group (HR corrected: 0.79; 95% CI: 0.60–1.05; p = 0.103).
Basal GA levels may predict the effect of ASA alone or of double antiplatelet therapy on the risk of
stroke recurrence, ischemic stroke and combined vascular events in acute patients with minor stroke or
high-risk TIA [117].
5. Discussion and Conclusions
The present review showed that, in some specific clinical conditions, GA offers significant
advantages for the monitoring of glycemic status compared to the currently available biomarkers used
in the clinical setting.
However, in some specific pathological conditions, especially those characterized by changes in
albumin metabolism (e.g., with increased albumin metabolism, such as in nephrotic syndrome and
in hyperthyroidism), the value of GA may underestimate the real value of the glycemia. Specifically,
in patients with kidney disease, the value of GA is reliable if the concentration of albumin in the urine
does not exceed 3.5 g/24 h [98,125].
Other alterations of GA due to chronic inflammation could be observed in smokers, in patients
with non-alcoholic liver disease, hypertriglyceridemia and hyperuricemia [126–128]. On the other hand,
in all conditions in which albumin metabolism is reduced (such as cirrhosis and hypothyroidism),
the GA levels are higher than the real mean glycemia and show some limitations in the monitoring of
the glycemic status due to the reduced synthesis of albumin [129]. Above all, in subjects with cirrhosis,
the GA/HbA1c ratio correlates with the liver function, allowing an indirect evaluation [130].
Although literature evidence supports the use of GA as a reliable biomarker for the assessment of
glycemic status, there is no consensus on the decisional values to use for different clinical conditions
(Table 1).
Table 1. Human clinical studies on GA cut-off values in the diagnosis and monitoring of therapies of







Cut-Off Value of GA
Monitoring Therapy
Cut-Off Value of GA
GA Parameters
Associated
(r = Correlation Coeff.)
Ref.
Diabetes Mellitus 1294 prediabetic patients >14.9% for diagnosingDiabetes [57]
Diabetes Mellitus 120 diabetic treatedwith SU











FPG, TG and LDL-C ↓
TC (r = 0.012)
LDL-C (r = 0.073)
[63]
Obesity 236 healthy non obeseand obese individuals
>13.77% for detecting
prediabetes BMI (r = 0.24) [77]








With a history of CV















diabetes HbA1c, hsCRP and CIMT [115]
BMI: Body Mass Index; CAD: Coronary Artery Disease; CIMT: Carotid Intima Media Thickness; FPG: Fasting
Plasma Glucose; CV: Cardiovascular; GA: Glycated Albumin; HbA1C: Hemoglobin A1c; hsCRP: high sensitivity
C Reactive Protein; LDL-C: Low Density Lipoprotein-Cholesterol; SU: Sulphonyl-urea; T2DM: Type 2 Diabetes
Mellitus; TC: Total Cholesterol; TG: Tri-Glycerides.
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In conclusion, GA has all the potential to be an excellent predictor of cardio-metabolic risk,
if evaluated in its fluctuations, compared to the metabolic parameters. However, additional studies are
needed to introduce GA in clinical practice.
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